Side-by-side · Research reference
GHRP-6vsOvagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1HUMAN-REVIEWED10/36 cited
BTheoreticalHUMAN-REVIEWED2/42 cited
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
Ovagen
Khavinson Bioregulator · Ovarian
OvarianTarget tissue
Di/Tri-peptidePeptide length
AnimalEvidence tier
Oral / SQ · Protocol varies
01Mechanism of Action
Parameter
GHRP-6
Ovagen
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation
Downstream effect
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration
Feedback intact?
—
Presumed physiological — Khavinson peptides described as regulatory, not replacement
Origin
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-6
Ovagen
Standard dose
100–200 mcg per injectionBowers 1990
10–20 mg / day (oral) or 1–2 mg SQ
Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.
Frequency
1–3× per day
Once daily or cyclical (10–20 days per month)
Cyclical protocols common in Khavinson bioregulator tradition.
Lower / starter dose
50 mcg per dose
—
Duration
8–12 weeks on / 4 off
4–12 weeks per cycle
Khavinson protocols typically 1–3 months; repeat cycles as needed.
Reconstitution
Bacteriostatic water
—
Timing
Pre-meal preferred for appetite support
—
Route
—
Oral (capsule) or subcutaneous
Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.
04Side Effects & Safety
Parameter
GHRP-6
Ovagen
Hunger
Pronounced — defining feature vs ipamorelin
—
Cortisol elevation
Mild
—
Prolactin elevation
Mild
—
Injection site reaction
Mild
Possible mild erythema (SQ route)
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
—
Reported adverse events
—
None documented in indexed literature
Theoretical hormonal effects
—
Ovarian stimulation — monitor for estrogen-sensitive conditions
Long-term safety
—
Unknown — no PubMed-indexed RCTs
Absolute Contraindications
GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
Ovagen
- ·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
- ·Pregnancy
Relative Contraindications
GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
Ovagen
- ·History of estrogen-sensitive tumors (monitor)
- ·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
- ·Endometriosis or fibroids (estrogen-responsive conditions)
05Administration Protocol
Parameter
GHRP-6
Ovagen
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.
2. Injection site
SQ — abdomen. Rotate sites.
1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.
3. Timing
Pre-meal for appetite support; pre-sleep for GH alignment.
Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
—